CN1537014B - 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 - Google Patents

用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 Download PDF

Info

Publication number
CN1537014B
CN1537014B CN028065670A CN02806567A CN1537014B CN 1537014 B CN1537014 B CN 1537014B CN 028065670 A CN028065670 A CN 028065670A CN 02806567 A CN02806567 A CN 02806567A CN 1537014 B CN1537014 B CN 1537014B
Authority
CN
China
Prior art keywords
hmgb1
cells
rage
hmg
migration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN028065670A
Other languages
English (en)
Chinese (zh)
Other versions
CN1537014A (zh
Inventor
马尔科·E·比安基
蒂齐亚纳·博纳尔迪
保拉·斯卡菲迪
苏珊·米勒
伯纳德·德格里希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio3 Research Srl
Original Assignee
Bio3 Research Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio3 Research Srl filed Critical Bio3 Research Srl
Publication of CN1537014A publication Critical patent/CN1537014A/zh
Application granted granted Critical
Publication of CN1537014B publication Critical patent/CN1537014B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN028065670A 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂 Expired - Fee Related CN1537014B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT2001MI000562A ITMI20010562A1 (it) 2001-03-16 2001-03-16 Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
ITMI2001A000562 2001-03-16
PCT/IT2002/000153 WO2002074337A1 (en) 2001-03-16 2002-03-12 Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN200910252323A Division CN101773669A (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Publications (2)

Publication Number Publication Date
CN1537014A CN1537014A (zh) 2004-10-13
CN1537014B true CN1537014B (zh) 2012-04-25

Family

ID=11447291

Family Applications (2)

Application Number Title Priority Date Filing Date
CN028065670A Expired - Fee Related CN1537014B (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
CN200910252323A Pending CN101773669A (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN200910252323A Pending CN101773669A (zh) 2001-03-16 2002-03-12 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂

Country Status (14)

Country Link
US (4) US7754217B2 (enExample)
EP (1) EP1368060B1 (enExample)
JP (1) JP4822654B2 (enExample)
CN (2) CN1537014B (enExample)
AT (1) ATE468137T1 (enExample)
AU (1) AU2002247977C1 (enExample)
CA (1) CA2439530C (enExample)
DE (1) DE60236413D1 (enExample)
DK (1) DK1368060T3 (enExample)
ES (1) ES2346408T3 (enExample)
IT (1) ITMI20010562A1 (enExample)
MX (1) MXPA03008364A (enExample)
PT (1) PT1368060E (enExample)
WO (1) WO2002074337A1 (enExample)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
HUP0500042A3 (en) * 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ATE424416T1 (de) 2002-07-03 2009-03-15 San Raffaele Centro Fond Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CA2882022A1 (en) 2003-09-11 2005-03-24 Walter Newman Monoclonal antibodies against hmgb1
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
PT1768677E (pt) * 2004-07-02 2008-10-06 Creabilis Therapeutics Spa Ácidos nucleicos para o tratamento de patologias relacionadas com hmgb1
US20090062187A1 (en) 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
MX2007001155A (es) * 2004-07-29 2007-08-14 Creabilis Therapeutics Spa Uso de inhibidores de k-252a y de quinasa para la prevencion o el tratamiento de patologias asociadas con hmgb1.
EP1797118A2 (en) * 2004-09-03 2007-06-20 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
WO2007001422A2 (en) 2004-10-22 2007-01-04 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
WO2006114805A2 (en) * 2005-04-28 2006-11-02 Fondazione Centro San Raffaele Del Monte Tabor Use of hmgb2 and hmgb3 proteins for medical applications
US20100040608A1 (en) 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
AU2006284096B2 (en) 2005-08-25 2012-03-29 Avro Life Sciences, Inc. Polymer conjugates of K-252a and derivatives thereof
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
CA2663300C (en) 2006-09-15 2014-10-07 Creabilis Therapeutics S.P.A. Polymer conjugates of box-a of hmgb1 and box-a variants of hmgb1
US8470325B2 (en) 2007-02-15 2013-06-25 Kagoshima University Method of treating amykloidosis comprising administering an anti-HMGB-1 antibody
RU2519714C2 (ru) 2008-04-30 2014-06-20 Дженомикс Ко., Лтд. Средство для вовлечения происходящей из костного мозга плюрипотентной стволовой клетки в периферический кровоток
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5582580B2 (ja) * 2009-07-16 2014-09-03 Ｎｅｃソリューションイノベータ株式会社 Ｈｍｇｂ１結合核酸分子およびその用途
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
CN102711777B (zh) 2009-10-28 2015-04-15 吉诺米克斯股份有限公司 利用骨髓间充质干细胞和/或多能干细胞的血中动员的组织再生促进剂
CA2847197C (en) 2010-10-30 2020-11-03 Isis Innovation Limited Treatment for dupuytren's disease
DK2703487T3 (en) 2011-04-26 2018-09-10 Genomix Co Ltd TIME TO INDUCTION Tissue Regeneration and its Use
US9244074B2 (en) * 2011-06-07 2016-01-26 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2012170742A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Treatment and prevention of cancer with hmgb1 antagonists
RU2647467C2 (ru) 2012-10-25 2018-03-15 Дженомикс Ко., Лтд. Новый способ лечения инфаркта миокарда с применением фрагмента hmgb1
EP2913059B1 (en) 2012-10-25 2018-04-11 Genomix Co., Ltd. Novel method for treating spinal cord injury using hmgb1 fragment
MX2015009547A (es) 2013-01-28 2015-11-25 Evec Inc Anticuerpo anti-hmgb1 humanizado o fragmento de union al antigeno del mismo.
IL242807A0 (en) * 2015-11-26 2016-04-21 Novamed Ltd Test facility
US11274132B2 (en) 2015-12-11 2022-03-15 Ruprecht-Karls-Universität Heidelberg Combined preparations of PKM2 modulators and HMGB1
BR112019014921A2 (pt) 2017-01-27 2020-03-31 StemRIM Inc. Agente terapêutico para miocardiopatia, infarto antigo do miocárdio e insuficiência cardíaca crônica
EP3719117A4 (en) 2017-12-01 2021-11-03 Stemrim Inc. EECTODERMAL MESENCHYMAL STEM CELLS AND METHOD FOR PRODUCING THEM
US11298403B2 (en) 2017-12-01 2022-04-12 StemRIM Inc. Therapeutic agent for inflammatory bowel disease
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
CN115361966B (zh) * 2020-04-22 2025-09-16 朱拉隆功大学 使dna恢复活力和防止dna损伤的组合物以及方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054122A (en) * 1990-11-27 2000-04-25 The American National Red Cross Supplemented and unsupplemented tissue sealants, methods of their production and use
US5470307A (en) * 1994-03-16 1995-11-28 Lindall; Arnold W. Catheter system for controllably releasing a therapeutic agent at a remote tissue site
WO1997026913A1 (en) 1996-01-26 1997-07-31 The Trustees Of Columbia University In The City Of New York A POLYPEPTIDE FROM LUNG EXTRACT WHICH BINDS AMYLOID-β PEPTIDE
US5864018A (en) * 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
WO1997039121A1 (en) 1996-04-16 1997-10-23 Schering Aktiengesellschaft Advanced glycosylation end-product receptor peptides and uses therefor
US6790443B2 (en) 1996-11-22 2004-09-14 The Trustees Of Columbia University In The City Of New York Method for treating symptoms of diabetes
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6398808B1 (en) 1999-06-15 2002-06-04 Scimed Life Systems, Inc. Localized delivery of genetic information from biostable materials
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
HUP0500042A3 (en) * 2001-05-15 2010-01-28 Long Island Jewish Res Inst Use of hmg fragments as anti-inflammatory agents
ITRM20040058A1 (it) * 2004-02-03 2004-05-03 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di regolare la proliferazione delle cellule muscolari lisce ed endoteliali.
US20090062187A1 (en) * 2004-07-20 2009-03-05 Marco Bianchi Use of Hmgb1 for Wound Healing
WO2008137552A2 (en) * 2007-05-02 2008-11-13 Medimmune, Llc Anti-rage antibodies and methods of use thereof

Also Published As

Publication number Publication date
JP2004523579A (ja) 2004-08-05
AU2002247977B8 (en) 2007-03-15
AU2002247977C1 (en) 2008-09-18
WO2002074337A1 (en) 2002-09-26
AU2002247977B2 (en) 2006-12-14
US20100297107A1 (en) 2010-11-25
DK1368060T3 (da) 2010-08-30
ES2346408T3 (es) 2010-10-15
EP1368060A1 (en) 2003-12-10
EP1368060B1 (en) 2010-05-19
AU2002247977A2 (en) 2004-02-26
ITMI20010562A1 (it) 2002-09-16
DE60236413D1 (de) 2010-07-01
US8058239B2 (en) 2011-11-15
US7754217B2 (en) 2010-07-13
US20100172896A1 (en) 2010-07-08
PT1368060E (pt) 2010-08-24
HK1069316A1 (en) 2005-05-20
CA2439530C (en) 2016-11-08
AU2002247977A1 (en) 2002-10-03
MXPA03008364A (es) 2004-11-12
US20080171052A1 (en) 2008-07-17
US20040136979A1 (en) 2004-07-15
CN1537014A (zh) 2004-10-13
ATE468137T1 (de) 2010-06-15
CA2439530A1 (en) 2002-09-26
CN101773669A (zh) 2010-07-14
WO2002074337A8 (en) 2003-08-28
JP4822654B2 (ja) 2011-11-24

Similar Documents

Publication Publication Date Title
CN1537014B (zh) 用于治疗血管病的hmgb1蛋白抑制剂和/或拮抗剂
Degryse et al. The high mobility group (HMG) boxes of the nuclear protein HMG1 induce chemotaxis and cytoskeleton reorganization in rat smooth muscle cells
JP2007051150A (ja) 結合組織増殖因子
JP2003523191A (ja) コアグラーゼ陰性ブドウ球菌からの５２ｋＤａ蛋白質及びそのフラグメント
WO2002036614A2 (en) Peptides for use in the treatment of alzheimer's disease
Ambort et al. Specific processing of tenascin-C by the metalloprotease meprinβ neutralizes its inhibition of cell spreading
CA2074361A1 (en) Merosin, nucleic acids encoding, fragments and uses thereof
KR100385293B1 (ko) βｉｇ-ｈ3의 일부 도메인을 이용한 세포 부착 및 창상치유 방법
Prakash et al. Fibroblast stimulation in schistosomiasis. XI. Purification to apparent homogeneity of fibroblast-stimulating factor-1, an acidic heparin-binding growth factor produced by schistosomal egg granulomas.
US7824868B2 (en) Formation of superfibronectin by BBK32 and uses therefor
US7517654B2 (en) Peptide and a derivative thereof promoting cell adhesion and spreading
Lambert et al. The interaction of Tamm-Horsfall protein with the extracellular matrix
HK1146703A (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
HK1069316B (en) Hmgb1 protein inhibitors and/or antagonists for the treatment of vascular diseases
EP0529348B1 (de) Verfahren zur Reinigung von Faktor XIII, monoklonale Antikörper gegen Faktor XIIIA, ihre Herstellung und Verwendung
CA3213181A1 (en) Mfap4 and treatment of fibrosis
JPH02311498A (ja) 機能性ポリペプチド
AU593063B2 (en) Purified human angiogenic factor, method for its preparation and pharmaceutical preparations
Yang et al. Aloe‐Emodin Targeting FOXC2 Disrupts NETs Formation and EMT‐Driven Postoperative Peritoneal Adhesion Through TGF‐β1‐Smad2/3 Pathway
Macleod IL-36 member activation and secretion, and their role in immune defence
Mihocik Isolation, purification, characterization and localization of a novel cysteine-rich glycoprotein (CRGP) of the extracellular matrix

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1069316

Country of ref document: HK

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Open date: 20041013

CI01 Publication of corrected invention patent application

Correction item: Rejection of patent application

Correct: Dismiss

False: Reject

Number: 32

Volume: 26

ERR Gazette correction

Free format text: CORRECT: PATENT APPLICATION REJECTION OF AFTER PUBLICATION; FROM: REJECTION TO: REVOCATION REJECTED

ASS Succession or assignment of patent right

Free format text: FORMER OWNER: BIANCHI MARCO E.

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20110125

Address after: Milan Italy

Applicant after: Bio3 Research S.R.L.

Address before: Milan Italy

Applicant before: Bio3 Research S.R.L.

Co-applicant before: Bianchi Marco E.

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1069316

Country of ref document: HK

CI01 Publication of corrected invention patent application

Correction item: Priority

Correct: MI2001A000562 2001.03.16 IT

Number: 17

Volume: 28

CI03 Correction of invention patent

Correction item: Priority

Correct: MI2001A000562 2001.03.16 IT

Number: 17

Page: The title page

Volume: 28

ERR Gazette correction

Free format text: CORRECT: PRIORITY DATA; FROM: NONE TO: MI2001A000562 2001.03.16 IT

RECT Rectification
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120425

Termination date: 20180312